Search

everythinglearnresearchcommunity

for

Search:↓

PRP, especially AA-PRP, can help improve hair growth in androgenetic alopecia.

PICAT is a reliable tool for assessing dermatology residents' skills in PRP procedures for hair loss.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

Genetic marker rs12558842 strongly linked to male hair loss.

Ritlecitinib is cost-effective for severe alopecia areata in Japan.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

A reliable method was developed to measure aristolochic acid-I in rat blood.

Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.

Intravenous delivery of autologous activated platelet-rich plasma is safe.

Mice studies show that Protein Phosphatase 2A is crucial for cell growth, development, and disease prevention.

Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.

rwSALT accurately measures hair regrowth in alopecia areata using scalp photos.

Platelet-rich plasma treatment significantly increased hair regrowth and decreased discomfort in alopecia patients, making it a potentially better and safer treatment option.

The herbal mixture RAA promotes hair growth and could be an alternative treatment for hair loss.

The document sets guidelines to standardize reporting of PRP clinical trials for better reproducibility and comparability.

Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.

Ritlecitinib is safe and may effectively treat alopecia areata.

Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.

Certain RNAs may help diagnose alopecia areata by affecting keratin genes.

Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.

Activated and non-activated PRP are equally safe and effective for treating alopecia areata.

Defective protein folding due to a mutation is key in ANE syndrome.

Ruxolitinib helped a patient with alopecia areata regrow hair.

Patients with RASopathies have a higher risk of autoimmune disorders and should be routinely screened.

ANE syndrome is caused by a mutation in the RBM28 protein that disrupts ribosome assembly.

Higher CRBP1 levels are linked to more severe alopecia areata.

PRP is effective for treating patchy alopecia areata.

PDRN from salmon may slow skin aging by improving skin quality and reducing inflammation.

Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.